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Abstract
Background: The purpose of this study was to evaluate the effectiveness of a patient education
program developed to facilitate statin adherence.
Methods: A controlled trial was designed to test the effectiveness of a multifaceted patient
education program to facilitate statin adherence. The program included a brief, in-office physician
counseling kit followed by patient mailings. The primary end point was adherence to filling statin
prescriptions during a 120-day period. Patients new to statins enrolled and completed a survey.
Data from a national pharmacy claims database were used to track adherence.
Results: Patients new to statin therapy exposed to a patient counseling and education program
achieved a 12.4 higher average number of statin prescription fill days and were 10% more likely to
fill prescriptions for at least 120 days (p = .01).
Conclusion:  Brief in-office counseling on cardiovascular risk followed by patient education
mailings can be effective in increasing adherence. Physicians found a one-minute counseling tool and
pocket guidelines useful in counseling patients.
Background
Effective management of lipid levels as risk factors for car-
diovascular disease requires long-term adherence to a
lipid lowering treatment regimen. However, studies con-
tinue to demonstrate lack of persistence in adhering to
cholesterol-lowering medicine therapy [1-6]. When indi-
viduals at risk for cardiovascular disease do not adhere to
prescribed medical regimens, medication benefits are not
fully achieved. Only half of individuals continue to take
prescribed statins at six months, with further declines in
adherence at one year [1]. This finding is consistent in
individuals who would benefit from primary prevention
with statins, as well as in those who have experienced a
cardiovascular event; it is especially prominent in asymp-
tomatic individuals, where such treatment is preventive
[6-8].
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Understanding and improving the quality of medication
management through the patient dialogue is a key issue in
adherence by patients treated for chronic diseases [1,9].
The communication of cardiovascular risk has been
linked to patients intensifying risk-reducing behaviors
and adhering to prescribed therapies [10]. Medication
side effects and cost issues that may lead to non-adherence
are frequently not discussed with physicians, a communi-
cation gap with important quality and safety implications
[11,12]. Providers may also not be using the most effec-
tive communication strategies when they do ask about
medication-taking behavior [9].
A review of randomized controlled trials evaluating the
effectiveness of interventions designed to facilitate patient
adherence to prescribed medications for chronic health
problems found that effective interventions were com-
plex, labor-intensive, and not predictably effective [5]. A
recent analysis addressing how adherence to statins could
be improved found that simplification of drug regimens,
patient information and education and intensified patient
care by healthcare professionals showed the most promise
[2]. At the present time, no fully effective strategies for
adherence are in widespread clinical use; innovative
approaches to assist patients in following prescriptions
have the potential to enhance the health of the public and
reduce healthcare costs [13]. Risk-communication inter-
ventions, however, have been associated with improved
patient knowledge, perception of risk, and adherence.
[14,15] The extra consultation time required for risk coun-
seling and shared decision-making has been associated
with benefits to the patient. [15]
When patients begin a new medical regimen, the regimen
requires behavioral changes both in implementation and
maintenance. The transtheoretical model has been used to
describe patients' willingness to make behavioral changes
that benefit their health. The model postulates that
patients, as they make changes such as adhering to a
newly prescribed medical regimen, evolve throughout six
stages: precontemplation, contemplation, preparation,
action, maintenance, and termination. [16] A review of
the use of the transtheoretical model in medication adher-
ence revealed that the model has not been used exten-
sively to investigate medication use, although the model
has shown promise as a context for developing interven-
tions to improve adherence. [17]
The purpose of this study was to evaluate the effectiveness
of an innovative patient educational program focused on
risk counseling, designed to facilitate patient adherence to
statin prescriptions. A secondary purpose was to deter-
mine whether the program would be more effective with
patients who take action proactively to preserve their
health.
Methods
Study design
A controlled trial was designed to test the effectiveness of
the Heart Health Counts (HHC) program. This patient edu-
cation program was designed to increase clarity in the car-
diovascular risk dialogue, in order to facilitate statin
adherence. The primary end point was adherence to filling
statin prescriptions during a 120-day period by patients
new to statin therapy.
To enroll, patients were asked to complete a consent form,
and to complete a survey. Patients were enrolled at the
time of a visit to their physician and were eligible to par-
ticipate if they were at least 40-years of age and receiving
a new prescription for statin therapy. Survey items of atti-
tudes and beliefs related to cardiovascular disease and
cholesterol management were included.
Identifying patients according to their attitudes concern-
ing health and lifestyle change has been shown to be
important in developing strategies to facilitate behavioral
change [16].
Based on their survey responses, patients were categorized
into three segments according to their health and medica-
tion attitudes: patients who regularly take action to pre-
serve their health, patients committed to their health but
not consistently taking action, and patients who do less to
preserve health.
Data on statin prescription use from a national pharmacy
claims database were used to determine whether or not
patients achieved 120 day adherence. Based on region,
prescription, age and gender, a control group of similar
patients not exposed to the patient education intervention
were identified from the national pharmacy claims data-
base. The Western Institutional Review Board approved
the study in October of 2006. Patients and physicians
completed a consent form agreeing to participate. Physi-
cians also completed a brief survey on their perceptions of
the program following use of the brief counseling materi-
als with their patients.
Eligibility criteria
Physicians were eligible to participate if they provided
adult primary care or were cardiologists. Physicians were
required to read the protocol, to complete a brief online
module concerning counseling patients with high choles-
terol, and to complete a consent form and letter of agree-
ment. Patients were eligible to participate if they are 40
years of age or older, had received a prescription for a
lipid-lowering agent within the past 30 days, had not pre-
viously been on a cholesterol-lowering medicine within
the past 12 months, were literate in English, and able toBMC Family Practice 2009, 10:48 http://www.biomedcentral.com/1471-2296/10/48
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give written consent to receive patient educational mail-
ings.
Power calculations indicated, within 95% confidence
intervals, a sample including at least 200 patients (includ-
ing 50 in each of two specific segments, those character-
ized as Health Preservers and those characterized as
Health Commiteds), a total of 100 patients was needed to
detect a 5% difference in adherence to statins at 120 days
comparing segments to a control group. In order to deter-
mine the number of patients required for enrollment, it
was estimated that each of the two segments of patients
who were ready to act to preserve their health were repre-
sentative of less than 10% of the total population, and a
smaller percentage of these would actually fill their pre-
scriptions. It was further estimated that 200 physicians
were needed to each recruit approximately 10 patients
with hypercholesterolemia new to statin therapy, a total
of 2000 patients. Physicians were each allowed to recruit
no more than 15 patients in order to ensure balanced rep-
resentation among the physicians recruited. Reflecting the
95% confidence intervals, the significance level was set at
.05.
Segmenting patients
Five questions from the 20-question survey were used to
segment patients into three groups. These questions were
used to create segments, but were not validated for this
purpose. Patients were asked to respond to the following
statements using a 7-point agreement scale: 1) I feel tired
most of the time 2) I feel older than I should 3) I do not
care what is in the medication, just that it works 4) I am
worried about the long-term side effects of medications
and 5) Taking medication makes me feel like I'm doing
everything I can to make myself better. Health Preservers
were more likely to agree with question #5 and less likely
to agree with questions 1,2,3, and 4. Health Committeds
were more likely to agree with question 3 but less likely to
agree with questions 1, 2 and 5. Others, those patients
who were less likely to focus on health preservation, were
more likely to agree with questions 1, 2, and 4, and less
likely to agree with questions 3 or 5.
Adherence measures
Data from a national pharmacy claims database were used
to determine adherence to filling statin prescriptions. The
average number of days for which statin prescriptions
were written was 30 days. However, the number of days
for which statin prescriptions were filled varied between
sites and depended on the site's current supplies. There-
fore, days of filled statin prescriptions were used in this
study, rather than the number of prescriptions filled. Two
adherence measures were calculated: 1) the average
number of days of prescriptions filled for statins per
patient during a 120-day time period, and 2) the percent-
age of patients who filled prescriptions for 120 days of sta-
tin therapy.
Intervention
The  HHC  program provided tools to physicians to
increase clarity in the cardiovascular risk dialogue, in
order to facilitate statin adherence. The program was
designed to facilitate an enhanced patient-physician dia-
logue without being labor-intensive for physicians and
other healthcare providers. Physicians participating in this
study received a counseling kit including 1) a set of 1-
minute health manager patient education tools used to
describe cholesterol risks, 2) patient contracts or pledges
designed to confirm a patient's commitment to the pre-
scribed medical regimen, 3) a copy of the National Cho-
lesterol Education Program pocket guidelines and 4) a set
of chart stickers. The materials were designed to address
cardiovascular risk and to provide a context for patients
who might be presented with a series of lab values but
might not have a context for the severity of the risk. The 1-
minute health manager and other HHC materials used
color coding with green, yellow, and red to represent car-
diovascular risk stratification, and to serve as a call to
action for patients in the yellow and red zones. By foster-
ing a more constructive patient-provider dialogue, a con-
text could be created for a patient-physician partnership in
developing achievable patient goals to reduce the risk of
cardiovascular disease.
Following the office visit, patients new to statin therapy
received 5 HHC  mailings over a 4-month period. The
four-color print mailings focused on various aspects of
cardiovascular health and cardiovascular risk.
Analysis
Descriptive statistics for categorical data were expressed as
percentages; for the continuous data, the descriptive statis-
tics were expressed as means (standard deviations). T-tests
were used to compare the average numbers of days statin
prescriptions were filled, and the percentage of patients
who completed 120 days of statin therapy. On questions
1 and 4, a reflect and square root transformation was per-
formed to normalize a distribution that differs only mod-
erately from normal. The deviation is more substantial for
questions 3 and 5, so we performed a reflect and inverse
transformation. Comparisons of segmented groups were
quantified by one-way multivariate analysis of variance
(MANOVA), followed by post-hoc pairwise comparisons
using the Student-Newman-Keuls (SNK) test and the
Dunnett T3 test for data sets with unequal variances. Sta-
tistical significance was established as p < 0.05. All analy-
ses were conducted using SPSS 16.0 (SPSS, Inc. Chicago,
IL).BMC Family Practice 2009, 10:48 http://www.biomedcentral.com/1471-2296/10/48
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Results
Patients were recruited for this study by 234 physicians
from 39 states. The specialties of participating physicians
were family medicine (59%), general internal medicine
(37%), and cardiology (4%). A total of 1,949 patients
consented, enrolled, and completed a survey. Of these,
1798 met the age requirement of 40 or more years of age
(Figure 1). Patient data were de-identified for the purpose
of obtaining pharmacy claims data. The average age of the
patients was 58 years; 24.8% were between 40 and 50
years of age, 34.0% between 50 and 60 years, 23.9%
between 60 and 70 years, and 17.3% over the age of 70.
When asked about how they would rate their health over-
all on a scale of 1–7 with 1 representing "poor" and 7 rep-
resenting "excellent," the average rating for the patient
group was 4.92.
Nearly all of the patients surveyed felt their physicians lis-
tened carefully to them and explained things in a way they
could understand. Most reported their physicians had
talked to them about their current cholesterol levels, the
health risks of high cholesterol, and about drug treat-
ments to lower cholesterol. However, 159 (8.8%)
reported "no" or "unsure" when asked whether their phy-
sician talked to them about setting goals for reducing cho-
lesterol, and 246 (13.6%) would not usually raise
concerns when their doctor does not ask about them.
(Table 1)
Of these enrolled patients, 913 were matched to the
claims database of pharmacy claims (Figure 1); 519 filled
at least one prescription during the treatment period of
the study (Table 2). However, of the 519 patients who
matched the claims database and filled at least one pre-
scription, 164 patients had filled a statin prescription dur-
ing the 12-month period before the initiation of the study
and were considered ineligible as a new statin user.
Around half of segment 1, Health Preservers, filled a new
statin prescription (46.9%). Table 3 represents the average
number of statin prescription days filled by participants
according to segments and the percentage of patients who
completed 120 days of new statin therapy. HHC partici-
pants achieved 12.4 more days on average of new statin
prescriptions filled compared to the control group (p =
.01). HHC participants were more likely to complete 120
days of statin therapy than similar patients who did not
participate (p = .01). Patients in the Health Preservers seg-
ment were more likely (although not statistically signifi-
cantly) to fill prescriptions for 120 days of statin therapy
than other patients participating in the program and sig-
nificantly more likely to fill prescriptions for the 120 days
of therapy compared with similar patients who did not
participate in the program (p = .01).
Flow Chart of Patient Enrollment and Exclusion Figure 1
Flow Chart of Patient Enrollment and Exclusion. A 
total of 1949 patients were enrolled in this study and com-
pleted a survey. For overall analysis, only patients that met 
the age criteria (40 and above) were included. Further exclu-
sions were made to analyze new statin patients that had filled 
at least prescription during the study period.BMC Family Practice 2009, 10:48 http://www.biomedcentral.com/1471-2296/10/48
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Table 4 represents patient attitudes concerning cardiovas-
cular risk related to elevated cholesterol. Utilizing one-
way MANOVA, we determined that the Health Preserver,
Health Committed, and other combined groups
responded significantly differently to questions concern-
ing cholesterol risk. Post hoc analysis using the SNK test
revealed that Health Committed patients were signifi-
cantly less likely to be concerned about their cholesterol
level than the Health Preservers or other combined
groups. However, both Health Committeds and Health
Preservers groups were less confident about their ability to
manage cholesterol levels than the other population seg-
ments. Based on the Dunnett T3 analysis, health commit-
ted patients differ from the other groups on whether high
cholesterol is linked to heart attacks. All three groups sig-
nificantly differed in their responses to whether taking
medication every day to lower cholesterol is worth it to
lower chances of a future heart attack. The Health Com-
mitteds group was most likely to be 1) concerned about
cholesterol levels 2) to believe that cholesterol makes a
difference in their overall health and 3) believe that peo-
ple with high cholesterol are more likely to have a heart
attack than people with low cholesterol. Both the Health
Committeds and Health Preservers groups were more
confident they could do what was needed to manage their
cholesterol and to believe that taking medicine very day to
Table 1: Physician patient communication by segment
Questions Health Preservers Health Committeds Others Total
yes no unsure yes no unsure yes no unsure yes no unsure
1. Has your physician talked to you 
about drug treatments to lower your 
cholesterol?
204
(97.6)
4
(1.9)
1
(0.5)
318
(97.5)
5
(1.5)
3
(0.9)
1231
(97.5)
18
(1.4)
14
(1.1)
1753
(97.5)
27
(1.5)
18
(1.0)
2. Has your physician talked to you 
about your current cholesterol levels?
205
(98.1)
3
(1.4)
1
(0.5)
319
(97.9)
7
(2.1)
0
(0)
1240
(98.2)
18
(1.4)
5
(0.4)
1764
(98.1)
28
(1.6)
6
(0.3)
3. Did your physician talk to you about 
health risks of high cholesterol?
203 (97.1) 4
(1.9)
2
(1.0)
318
(97.5)
5
(1.5)
3
(0.9)
1210
(95.8)
30
(2.4)
23 (1.8) 1731
(96.2)
39
(2.1)
28
(1.6)
4. Has your physician talked to you 
about your cholesterol goals?
195
(93.3)
6
(2.9)
8
(3.8)
301
(92.3)
13
(4.0)
12
(3.7)
1143
(90.5)
64
(5.1)
56
(4.4)
1639
(91.2)
83
(4.6)
76
(4.2)
5. Do you feel your doctor has listened 
carefully to you?
202
(96.7)
1
(0.5)
6
(2.9)
323
(99.1)
2
(0.6)
1
(0.3)
1223
(96.8)
10
(0.8)
30
(2.4)
1639
(97.2)
13
(0.7)
37
(2.1)
6. Do you feel your doctor has 
explained things in a way you could 
understand?
201
(96.2)
2
(1.0)
6
(2.9)
320
(98.2)
3
(0.9)
3
(0.9)
1226
(97.1)
11
(0.9)
26
(2.1)
1747
(97.2)
16
(0.8)
35
(1.9)
7. Do you usually raise your concerns 
even when your doctor does not ask?
186
(89.0)
13
(6.2)
10
(4.8)
288
(88.3)
24
(7.4)
14
(4.3)
1078
(85.4)
124
(9.8)
61
(4.8)
1552
(86.3)
161
(8.9)
85
(4.7)
* Percentages of responses are in parentheses.
Table 2: Patients matched to pharmacy claims database by segment
Patients By Segment Matched to Claims Data1
(N)
New Statin Script Filled2
(N)
Matched Patients Filling Statin Script
(%)
Health Preservers 98 46 46.9%
Health Committeds 165 66 40.0%
Others 650 243 37.4%
Total Heart Health Counts Patients 913 355 38.9%
1 Patients who had previously filled prescriptions in pharmacies associated with the national pharmacy claims database were matched to the claims 
database; they did not, however, fill a statin prescription during the study period at a pharmacy covered by the claims database.
2 Patients who filled a new statin prescription in pharmacies associated with the national pharmacy claims databaseBMC Family Practice 2009, 10:48 http://www.biomedcentral.com/1471-2296/10/48
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lower cholesterol is worth it to lower risks of a future heart
attack.
One hundred and sixty-four physicians who recruited
patients returned surveys after they used the HHC coun-
seling kits in their office. Of these 93.3% felt the kits were
easy to use; 87.8% felt the kit allowed them to clearly
explain cardiovascular risk factors to their patients and
62.2% felt the kit helped their patients make positive life-
style changes. Participating physicians identified the 1-
minute cardiovascular risk manager for brief counseling
as the most useful tool provided in the counseling kit
(Table 5), followed by the NCEP ATP III Pocket Guidelines.
Discussion
While the use of statin medication has clinically proven
benefits in the treatment of heart disease, one of the well-
documented barriers to its use is the large number of
patients who do not fill the prescription, or stop use
within the first year. Improving adherence to a treatment
plan may result from a better understanding by the indi-
vidual of personal risk as well as of the disease process and
the role of statin medication in reducing cardiovascular
Table 3: Days of new statin prescriptions filled
Enrolled Patient Segments N Mean # Days* p value % Completing 120 days* Segments Compared to Control
p value
Health Preservers 46 87.2 0.01 72.8 0.01
Health Committeds 66 77.5 0.05 65.3 0.05
Others 243 80.9 <0.01 67.5 0.01
All Heart Health Counts Patients 355 81.1 <0.01 67.8 <0.01
All Control Patients 196 68.7 - 57.8 -
Table 4: Patient attitudes concerning cardiovascular risk related to elevated cholesterol
Question N % Mean SD F P ηp
2 SNK Dunnett T3
How concerned are you about your cholesterol level? P
C
O
Total
209
326
1263
1798
11.6
18.1
70.3
100.0
5.83
6.19
5.75
5.84
0.089
0.065
0.036
0.030
18.766 <0.001 0.004 C<P
C<R
P≠C
C≠R
My cholesterol level does not make a big difference to 
my total overall health.
P
C
O
Total
209
326
1263
1798
11.6
18.1
70.3
100.0
2.84
3.30
2.98
3.02
0.149
0.138
0.059
0.051
3.662 0.026 0.004
People with high cholesterol are more likely to have a 
heart attack than people with low cholesterol.
P
C
O
Total
209
326
1263
1798
11.6
18.1
70.3
100.0
6.23
6.44
6.14
6.20
0.090
0.061
0.035
0.029
15.048 <0.001 0.016 C≠other
I am confident I can do what is needed to manage my 
cholesterol.
P
C
Other
Total
209
326
1263
1798
11.6
18.1
70.3
100.0
6.03
6.03
5.71
5.81
0.087
0.073
0.036
0.031
14.907 <0.001 0.016 P < R
C < R
P ≠ other
C ≠ other
Taking medicine every day to lower cholesterol is 
worth it to me to lower the chances of having a heart 
attack in the future.
P
H
O
Total
209
326
1263
1798
11.6
18.1
70.3
100.0
6.40
6.62
6.26
6.34
0.079
0.047
0.032
0.026
19.812 <0.001 0.022 P≠C
C≠R
P = Health Preservers
C = Health Committeds
O = OthersBMC Family Practice 2009, 10:48 http://www.biomedcentral.com/1471-2296/10/48
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risk. The HHC program has focused on the communica-
tion of cardiovascular risk in the dialogue between patient
and physician in order to motivate the patient to adhere
to the prescribed medical regimen.
Patients participating in the HHC study filled more pre-
scriptions than control patients who were not exposed to
the program. Based on the research highlighting the diffi-
culties associated with labor-intensive interventions [2,5],
the program was designed to intensify the physician
patient dialogue without becoming labor intensive. The
Heart Health Counts program aimed at maximizing the
limited amount of time a physician might spend with a
patient during the patient encounter by providing a sim-
ple, well-designed 1-minute risk counseling tool. Physi-
cians stressed the benefits of the 1-minute cardiovascular
risk manage tool and a pocket cholesterol management
guideline, reporting that these tools facilitated patient
management.
Given the scarce resources available for increasing adher-
ence, the concept of segmentation for health education
based on health beliefs has the potential to identify those
patients who will benefit most from additional coun-
seling and reinforcement of the benefits from a given
treatment plan. The Heart Health Counts program was
most effective with those individuals classified as Health
Preservers, a group whose beliefs included a commitment
to actively preserving their health. Physician-patient com-
munication may be enhanced when a physician better
understands a patient's approach to his/her own care [18-
20] More research is needed, however, to better under-
stand how to best design tailored interventions.
This study was limited in several ways. The use of prescrib-
ing data from retail pharmacies as a data source presents a
series of limitations. The claims database captured com-
mercial pharmacy data, but did not capture all events
related to patient pharmacy claims Patients may have
filled prescriptions in some other setting, by mail, or not
at all. Using a national claims database does not allow a
complete study of nonadherence since not all patients are
represented in the database. Patient prescribing data is
deidentified and aggregated by segment; thus, prescrip-
tion data could not be connected to survey data. Filling a
prescription did not actually guarantee taking the medi-
cine. In future studies, more robust measures of adherence
could track actual medication use by recording the dates
and times of medicine bottle opening with electronic
caps.
The study was also limited by the study period, where
adherence was measured at 120 days. A longer period of
follow-up would provide a more in-depth look at adher-
ence patterns. The current study was not designed to track
actual exposure to the mailed materials, leaving open the
research question concerning the effectiveness of whether
tailored mailed patient education materials increase statin
adherence. Future research to attempt to resolve this ques-
tion could include the use of emerging technologies, such
as Internet sites that would allow tracking exposure to
educational messages.
Conclusion
In conclusion, providing tools to physicians to improve
the quality of the physician-patient dialogue around car-
diovascular risk shows promise in addressing the impor-
tant issue of facilitating long-term adherence to statin
therapy. Tools that increase the clarity of risk communica-
tion but do not add significantly to the labor of healthcare
professionals are those that are most valuable in daily
clinical practice.
Little attention has been paid in medical school and resi-
dency training programs in teaching physicians the best
ways to communicate cardiovascular risk and to motivate
patients to adhere to the prescribed medical regimens that
prevent cardiovascular disease. Providing physicians and
other healthcare professionals with tools to make the dia-
logue during the patient encounter more effective and effi-
cient may significantly enhance patient adherence.
Strategies that provide follow up for patients through
reminders may reinforce the messages from this dialogue.
Patients vary in their attitudes towards their health and in
taking on a new medical regimen. One size does not fit all
Table 5: Ratings of usefulness of Heart Health Counts kit components N = 164
C o m p o n e n t s L e a s t  1 234M o s t  5
One-Minute Health Manager Profile 0.6% 3.7% 21.5% 39.9% 34.4%
Hearth Health Counts Pledge 5.0% 20.5% 31.1% 26.1% 17.4%
Chart Stickers 18.6% 19.9% 28.0% 21.7% 11.8%
NCEP ATP III Pocket Guidelines 3.7% 2.5% 19.6% 39.9% 34.4%Publish with BioMed Central    and   every 
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in patient education and counseling. Simple strategies
that support the physician-patient dialogue and those that
provide reminders to patients about the need to reduce
cardiovascular risk may have a significant impact on
improving patient adherence and preventing cardiovascu-
lar disease.
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